NovoCure Ltd (NVCR) income statement
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3033% below fair value
$10.73−0.41 (-3.68%)
Close on Nov 18, 2026Market cap $1.25BP/E –Yield –
NovoCure Ltd income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 77.0%
- Operating margin
- -17.2%
- Net margin
- -16.8%
- Return on equity, FY2025
- -38.9%
Financial strength
- Current ratio
- 2.49
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 35.7%
Valuation
- P/E ratio
- –
- Price to sales
- 1.73
- Price to book
- 3.58
- Dividend yield
- –
See a number that looks wrong?